Background The magnitude of effect of sodium-glucose cotransporter-2 inhibitors (SGLT2i)
on specific cardiovascular and renal outcomes and whether heterogeneity is based on key …

This paper considers the argument for obesity as a chronic relapsing disease process.
Obesity is viewed from an epidemiological model, with an agent affecting the host and …

A modern approach to obesity acknowledges the multifactorial determinants of weight gain
and the health benefits to be derived from weight loss. Foundational to any weight loss effort …

Background The cardiovascular safety profile of dapagliflozin, a selective inhibitor of sodium–
glucose cotransporter 2 that promotes glucosuria in patients with type 2 diabetes, is …

Background Obesity is a global health challenge with few pharmacologic options. Whether
adults with obesity can achieve weight loss with once-weekly semaglutide at a dose of 2.4 …

Background Obesity is a chronic disease with serious health consequences, but weight loss
is difficult to maintain through lifestyle intervention alone. Liraglutide, a glucagon-like …

Objectives: An apparent increase in seriously disturbed students consulting student health
services in the UK has led to concern that increasing financial difficulties and other outside …

Background Liraglutide 3· 0 mg was shown to reduce bodyweight and improve glucose
metabolism after the 56-week period of this trial, one of four trials in the SCALE programme …

Aims Obstructive sleep apnoea (OSA) is associated with increased cardiovascular morbidity
and mortality. Although it was previously assumed that this was due to its relation with …

The American Diabetes Association, JDRF, the European Association for the Study of
Diabetes, and the American Association of Clinical Endocrinologists convened a research …